58 search results for: symposium

expert video

UCARE 2023: Potential Role of Type 2 Cytokines in CSU Pathogenesis

2 min

Dermatology

Dr. Saini summarises the potential role of type 2 cytokines in the pathogensis of CSU.

expert video

Challenges Faced by Dermatologists When Managing Atopic Dermatitis in Children - Expert Interview

8 min

Dermatology

Watch ADVENT now: Dermatologist Mark Koh describes the Challenges Faced by Dermatologists When Managing Atopic Dermatitis in Children.

expert video

New Perspectives in Understanding the Pathophysiology of Atopic Dermatitis in Children - Expert Interview

7 min

Dermatology

Watch ADVENT now: Dermatologist Stephan Weidinger explores the pathophysiology and current unmet needs in pediatric atopic dermatitis

expert video

Practical Considerations for the Management of Children With Moderate-to-severe Atopic Dermatitis - Expert Interview

9 min

Dermatology

Watch ADVENT now: Dermatologist Amy Paller discusses unmet needs and therapeutic considerations for pediatric patients with atopic dermatitis

expert video

Targeted Therapies for Children With Atopic Dermatitis - Expert Interview

9 min

Dermatology

Dermatologist Elaine Seigfried discusses burden & therapeutic landscape of pediatric atopic dermatitis

expert video

Challenges Faced by Dermatologists When Managing Atopic Dermatitis in Children - Expert Interview (Copy)

8 min

Dermatology

Watch ADVENT now: Dermatologist Mark Koh describes the Challenges Faced by Dermatologists When Managing Atopic Dermatitis in Children.

expert video

Contribution of Type 2 Cytokines to Inflammation and Itch in AD, PN, and CSU

3 min

Dermatology

Dr. Marta Ferrer describes the roles of type 2 cytokines in the processes involved in AD, PN, and CSU pathogenesis.

expert video

Overview of Type 2 Inflammation in the Presentations of AD, PN, and CSU

2 min

Dermatology

Dr. Eric Simpson summarizes the role of type 2 inflammation in the clinical manifestations of AD, PN, and CSU.

expert video

Differences in Itch in AD, PN, and CSU

2 min

Dermatology

Dr. Shawn Kwatra reviews the distinct characteristics of itch, and the associated patient burden in AD, PN, and CSU.

expert video

Importance of Achieving Disease Control in Adults With Moderate-to-Severe AD

20 min

Dermatology

This video features Dr. Eric Simpson's presentation on the importance of achieving disease control in adults with moderate-to-severe AD. Dr. Simpson discusses how adult patients and HCPs talk about disease control and the tools available to help define it. He also explores the roles of IL-4 and IL-13 in the pathophysiology of AD, including how both cytokines promote inflammation and, in turn, contribute to the cumulative burden of the disease. The video concludes with a brief panel discussion.

expert video

What do we mean by disease control in AD?

3 min

Dermatology

Dr. Eric Simpson discusses the differing goals of patients and physicians in treating atopic dermatitis and emphasizes the importance of patient input.

expert video

What Drives PN Disease? Exploring the Complexity of PN Pathophysiology

15 min

Dermatology

Dr. Brian Kim discusses the numerous contributors to PN pathophysiology, including type 2 inflammation, neuronal dysfunction, and dermal fibrosis, emphasizing the unique and overlapping roles of IL 31, IL-4 and IL-13 in its pathology.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: SwitzerlandChange country/region